文献速递骨肌介入MR

MRI评估犬骨肉瘤比较肿瘤学模型中的组织碎裂术消融

MRI for the Assessment of Histotripsy Ablation in a Canine Osteosarcoma Comparative Oncology Model.
PubMed 文献 · Ultrasound Med Biol · 2025-10-17

本研究回顾性分析8只自发犬骨肉瘤接受组织碎裂术治疗前后的MRI,评估消融区表现并与大体解剖和病理对照。消融区在增强序列上呈无强化低信号,MRI与大体测量无显著差异,MRI与病理的肿瘤成骨评分显著正相关。提示MRI可用于评估骨肿瘤组织碎裂术消融。

要点

  • 增强T1加权序列(含或不含减影)可可靠显示组织碎裂术消融区为无强化低信号区。
  • 靶向肿瘤区归一化平均信号强度在组织碎裂术前后显著下降。
  • MRI与大体测量的消融尺寸和体积无显著差异,病理证实消融区与MRI所见一致。

核心结论

  • MRI是评估骨肉瘤组织碎裂术消融的有价值工具,支持组织碎裂术作为犬和人骨肿瘤非侵入性治疗的潜力。

研究设计与样本

  • 回顾性分析兽医临床试验的MRI资料,8只犬接受组织碎裂术治疗部分肿瘤,治疗前后行平扫和增强T1及T2加权MRI,随后行标准手术切除;定性评估MRI消融表现并与大体解剖和病理对照,定量测量MRI与大体消融尺寸和体积,并对未治疗肿瘤的成骨在MRI与病理上评分比较。

关键影像表现/征象

  • 所有犬的消融区在增强序列上表现为无强化、低信号区。
  • 靶向肿瘤区归一化平均信号强度从组织碎裂术前到术后显著下降。
  • MRI与大体测量的消融尺寸和体积无显著差异。
  • 病理证实大体和MRI识别的靶向区域消融,MRI与病理的肿瘤骨成分评估显著正相关。

临床应用与阅片要点

  • 增强T1加权序列(含或不含减影)可用于显示组织碎裂术消融区,表现为无强化低信号。
  • MRI测量消融尺寸和体积与大体测量无显著差异,可用于评估消融范围。
  • MRI评估肿瘤成骨与病理评分显著正相关,可反映肿瘤成分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To explore the use of MRI for evaluation of mechanical focused ultrasound (histotripsy) ablation in spontaneous canine osteosarcoma (OS) as a comparative oncology model of human OS.

METHODS: A retrospective analysis was conducted on MR images from a veterinary clinical trial, with the purpose of using canine OS as a preclinical model in which to study human OS. Eight dogs received histotripsy treatment to a portion of their tumor, with pre- and post-treatment MRI (pre- and post-contrast T1- and T2-weighted). Dogs then received standard-of-care surgical resection. Qualitative assessments included characterization of ablation on MRI, gross anatomy, and histopathology. Quantitative assessments included measurements of ablation on MRI and gross anatomy, as well as scoring tumor bone production in untreated tumor on MRI and histopathology to compare tumor composition assessments across modalities.

RESULTS: Contrast-enhanced sequences with and without subtraction reliably visualized histotripsy ablation. For all dogs, the ablation zone was visible as a nonenhancing, hypointense region. There was a significant decrease in normalized mean signal intensity of the targeted tumor region from pre- to post-histotripsy. No significant differences were found between MRI and gross measurements of ablation dimensions and volume. Histopathology confirmed ablation in the targeted regions as identified grossly and on MRI, and tumor bone composition assessments on MRI and histopathology had a significant positive correlation.

CONCLUSIONS: MRI is a valuable tool for the assessment of histotripsy ablation in OS and builds upon the potential of histotripsy as a non-invasive therapy for bone tumors in dogs and humans.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Vickers ER, Ruger LN, Coutermarsh-Ott SL, et al. MRI for the Assessment of Histotripsy Ablation in a Canine Osteosarcoma Comparative Oncology Model. Ultrasound Med Biol. 2025. PMID: 41109828. doi:10.1016/j.ultrasmedbio.2025.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。